Aelis Farma’s Phase 2b trial of AEF0217 in Down syndrome cleared its first IDMC safety review with no safety concerns. Recruitment remains on track for 2026 completion.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Aelis Farma announced that the Independent Data Monitoring Committee (IDMC) has recommended continuation of the ongoing Phase 2b AEF0217‑201 trial in adolescents and adults with Down syndrome, following review of blinded safety data. The committee identified no new safety concerns and advised that the randomized, placebo‑controlled study proceed without protocol modifications.
The first scheduled safety assessment included 42 randomized participants, of whom 32 had completed at least four weeks of treatment as of the June 4, 2026 cutoff. No severe or serious adverse events were reported. All adverse events were mild, none were considered related to AEF0217, and no participant discontinued treatment due to adverse events.
Mechanism of Action
AEF0217 is a first‑in‑class Signaling Specific inhibitor of the cannabinoid receptor type 1 (CB1‑SSi). Unlike earlier CB1 antagonists that broadly blocked receptor function and caused limiting side effects, CB1‑SSi compounds mimic a natural regulatory mechanism, selectively reducing pathological CB1 signaling while preserving normal receptor activity. Aelis Farma is developing AEF0217 as a potential treatment for cognitive impairment and adaptive behavior deficits in Down syndrome, an area with no approved pharmacological therapies.
Phase 2b Trial Progress
The AEF0217‑201 study (NCT07334912) is a randomized, double‑blind, placebo‑controlled, multicenter Phase 2b trial enrolling 188 participants aged 16 to 32 years across France, Spain, and Italy. Participants receive once‑daily AEF0217 at 0.1 mg, 0.2 mg, or 0.6 mg, or placebo, over 24 weeks. The primary endpoint assesses adaptive behavior, with secondary measures including cognition, sleep, quality of life, safety, and tolerability. Recruitment is on schedule, with 65 participants randomized and five undergoing randomizations, representing ~37% of planned enrollment.
Clinical Perspective
CEO Pier Vincenzo Piazza stated that the IDMC’s recommendation strengthens confidence in the CB1‑SSi approach. He emphasized the absence of treatment‑related adverse events and the consistency of the safety profile across prior studies, reinforcing the compound’s selective mechanism of action.
Development Path
Aelis Farma expects to complete enrollment by end‑2026, with topline Phase 2b results anticipated by end‑2027. The next IDMC review will occur after at least 40 participants complete 12 weeks of treatment. The trial is conducted within the European H2020 ICOD project, which has received €6 million in European Commission funding to support therapies targeting cognitive impairment in Down syndrome.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.